Literature DB >> 21502551

Will evidence ever be sufficient to resolve the challenge of cost containment?

Arthur L Caplan.   

Abstract

Mesh：

Year:  2011        PMID： 21502551     DOI： 10.1200/JCO.2011.34.7039

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

Review 1.  Bevacizumab in the treatment of metastatic breast cancer: friend or foe?

Authors:  Alberto J Montero; Mauricio Escobar; Gilberto Lopes; Stefan Glück; Charles Vogel
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

2.  What is the evidence for our standards of care?

Authors:  Laurence A Turka; Arthur Caplan
Journal:  J Clin Invest       Date:  2011-07-01       Impact factor: 14.808

3.  Drug waste minimization as an effective strategy of cost-containment in oncology.

Authors:  Gianpiero Fasola; Giuseppe Aprile; Luisa Marini; Alessandro Follador; Mauro Mansutti; Manuela Miscoria
Journal:  BMC Health Serv Res       Date:  2014-02-07       Impact factor: 2.655

4.  Lack of proportionality. Seven specifications of public interest that override post-approval commercial interests on limited access to clinical data.

Authors:  Daniel Strech; Jasper Littmann
Journal:  Trials       Date:  2012-07-02       Impact factor: 2.279
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.